focus -WSS

focus

author：comprehensive 2025-09-27 16:47:46 - browse：21

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Medicaid rebukes states for mistakenly disenrolling children

WSS

AI gets buy

Covid hospitalizations on the rise, Humana says

The (many) problems with a new study criticizing cancer screening

NIH nominee Bertagnolli will get October confirmation hearing

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Listen: Biogen's potential pivot, & Illumina's next chapter

knowledge

focus

knowledge

Moonlake's readout produced a cash windfall. Risks remain

A single Democrat is willing to weaken Medicare negotiation power

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Stem cell treatment guidelines are released by FDA

Apple is now the first public company to be valued at $3 trillion

Medicaid rebukes states for mistakenly disenrolling children

ChatGPT in medicine: STAT answers readers' burning questions

Listen: Biogen's potential pivot, & Illumina's next chapter

Moonlake's readout produced a cash windfall. Risks remain

Why Novartis is changing the name of its research labs

hotspot

Medicaid rebukes states for mistakenly disenrolling children

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Crinetics acromegaly drug succeeds in late

The (many) problems with a new study criticizing cancer screening

Problems with a popular proposal to regulate AI in health care

Why Novartis is changing the name of its research labs

focus

Wikipedia

hotspot

leisure time